These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 21810649)

  • 21. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.
    Street JS; Clark WS; Gannon KS; Cummings JL; Bymaster FP; Tamura RN; Mitan SJ; Kadam DL; Sanger TM; Feldman PD; Tollefson GD; Breier A
    Arch Gen Psychiatry; 2000 Oct; 57(10):968-76. PubMed ID: 11015815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials.
    Grossberg GT; Kohegyi E; Mergel V; Josiassen MK; Meulien D; Hobart M; Slomkowski M; Baker RA; McQuade RD; Cummings JL
    Am J Geriatr Psychiatry; 2020 Apr; 28(4):383-400. PubMed ID: 31708380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
    Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Lyons B; Grossman F
    J Clin Psychiatry; 2003 Feb; 64(2):134-43. PubMed ID: 12633121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.
    Clark WS; Street JS; Feldman PD; Breier A
    J Clin Psychiatry; 2001 Jan; 62(1):34-40. PubMed ID: 11235926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of valproic acid versus haloperidol in patients with acute agitation: results of a randomized, double-blind, parallel-group trial.
    Asadollahi S; Heidari K; Hatamabadi H; Vafaee R; Yunesian S; Azadbakht A; Mirmohseni L
    Int Clin Psychopharmacol; 2015 May; 30(3):142-50. PubMed ID: 25500684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tolerability of extended-release quetiapine fumarate compared with immediate-release quetiapine fumarate in older patients with Alzheimer's disease with symptoms of psychosis and/or agitation: a randomised, double-blind, parallel-group study.
    De Deyn PP; Eriksson H; Svensson H;
    Int J Geriatr Psychiatry; 2012 Mar; 27(3):296-304. PubMed ID: 21538537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease.
    Kirbach S; Simpson K; Nietert PJ; Mintzer J
    Clin Drug Investig; 2008; 28(5):291-303. PubMed ID: 18407715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies.
    Wilcock GK; Ballard CG; Cooper JA; Loft H
    J Clin Psychiatry; 2008 Mar; 69(3):341-8. PubMed ID: 18294023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.
    Cummings JL; Schneider E; Tariot PN; Graham SM;
    Neurology; 2006 Jul; 67(1):57-63. PubMed ID: 16832078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease.
    Streim JE; Porsteinsson AP; Breder CD; Swanink R; Marcus R; McQuade R; Carson WH
    Am J Geriatr Psychiatry; 2008 Jul; 16(7):537-50. PubMed ID: 18591574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal relationships between Alzheimer disease progression and psychosis, depressed mood, and agitation/aggression.
    Zahodne LB; Ornstein K; Cosentino S; Devanand DP; Stern Y
    Am J Geriatr Psychiatry; 2015 Feb; 23(2):130-40. PubMed ID: 23871118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design.
    Devanand DP; Mintzer J; Schultz S; Sultzer D; de la Pena D; Gupta S; Colon S; Schimming C; Pelton GH; Andrews H; Levin B
    Am J Geriatr Psychiatry; 2012 Apr; 20(4):362-73. PubMed ID: 21407047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lithium Treatment for Agitation in Alzheimer's disease (Lit-AD): Clinical rationale and study design.
    Devanand DP; Strickler JG; Huey ED; Crocco E; Forester BP; Husain MM; Vahia IV; Andrews H; Wall MM; Pelton GH
    Contemp Clin Trials; 2018 Aug; 71():33-39. PubMed ID: 29859917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sodium valproate in the treatment of behavioral disturbance in dementia.
    Mellow AM; Solano-Lopez C; Davis S
    J Geriatr Psychiatry Neurol; 1993; 6(4):205-9. PubMed ID: 8251047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder.
    Macritchie KA; Geddes JR; Scott J; Haslam DR; Goodwin GM
    Cochrane Database Syst Rev; 2001; (3):CD003196. PubMed ID: 11687047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis.
    Ballard CG; Coate B; Abler V; Stankovic S; Foff E
    Int J Geriatr Psychiatry; 2020 Nov; 35(11):1402-1408. PubMed ID: 32729631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial.
    Schneider LS; Frangakis C; Drye LT; Devanand DP; Marano CM; Mintzer J; Mulsant BH; Munro CA; Newell JA; Pawluczyk S; Pelton G; Pollock BG; Porsteinsson AP; Rabins PV; Rein L; Rosenberg PB; Shade D; Weintraub D; Yesavage J; Lyketsos CG;
    Am J Psychiatry; 2016 May; 173(5):465-72. PubMed ID: 26771737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
    Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S;
    Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of melatonin versus valproic acid in prophylaxis of migraine patients: A double-blind randomized clinical trial.
    Ebrahimi-Monfared M; Sharafkhah M; Abdolrazaghnejad A; Mohammadbeigi A; Faraji F
    Restor Neurol Neurosci; 2017; 35(4):385-393. PubMed ID: 28800342
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Placebo-controlled study of divalproex sodium for agitation in dementia.
    Porsteinsson AP; Tariot PN; Erb R; Cox C; Smith E; Jakimovich L; Noviasky J; Kowalski N; Holt CJ; Irvine C
    Am J Geriatr Psychiatry; 2001; 9(1):58-66. PubMed ID: 11156753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.